Vertex Pharmaceuticals
Price & Volume
Stats
See more52W Range | $377.85-$519.88 |
Market Cap | $102.3B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $10.6B |
Revenue Growth (YoY) | 11.6% |
Gross Profit (12 Mos) | $5.3B |
Diluted EPS | -$1.90 |
News
See moreYahoo Finance • 3 months ago
Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
Yahoo Finance • 3 months ago
Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Yahoo Finance • 3 months ago
Prediction: These 3 Phenomenal Stocks Are Set to Soar
Yahoo Finance • 3 months ago
Vertex Pharmaceuticals Incorporated (VRTX): Why Do Hedge Funds Recommend This Biotech Stock?
About
CEO | Dr. Reshma Kewalramani FASN, M.D. |
CFO | Mr. Charles F. Wagner Jr. |
Address | 50 Northern Avenue, Boston, MA, United States, 02210 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 5,400 |
